Changes of Muscle Insulin-like Growth Factor-I and Concentrations of Inflammatory Cytokines in Rat Skeletal Muscle Following Denervation and Diabetes-induced Atrophy
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
[PURPOSE] Muscle atrophy is the result of several diseases and conditions. In systemic disease, many factors contribute to muscle atrophy. Insulin-like growth factor-I (IGF-I) is a local and systemic hormone that contributes to muscle growth. The aim of this study was to investigate the changes in muscle protein synthesis biomarkers and pro-inflammatory factors associated with muscle atrophy in systemic disease. [METHODS] Local muscle tissue damage was observed and compared in both streptozotocin (STZ) -induced diabetic and denervated rats. In these animal models, we measured the expression of muscle-specific IGF-1 (mIGF-1) in by real-time PCR and serum concentrations of inflammatory cytokines by ELISA. In addition, muscle mass and blood glucose levels were observed for six weeks. [RESULTS] The results showed that muscle mass was significantly lower in both experimental groups compared to the control group from week two. Over the six week period, muscle mass gradually increased in the control group, dramatically decreased in the denervated group, but interestingly, showed no significant changes in the diabetes group. Inflammatory factors including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) were significantly higher in diabetic rats than in the control group. The level of TNF-α was increased at week four; however, IL-6 levels did not change in denervated rats. The expression of mIGF-1 mRNA did not change significantly in the two experimental groups. [CONCLUSIONS] In conclusion, mIGF-1 for the proliferation of muscle cells did not have an effect on muscle atrophy among the groups. However the increase in systemic inflammatory factors may be involved in the process of muscle atrophy in diabetic rats.
Abstract
[PURPOSE] Muscle atrophy is the result of several diseases and conditions. In systemic disease, many factors contribute to muscle atrophy. Insulin-like growth factor-I (IGF-I) is a local and systemic hormone that contributes to muscle growth. The aim of this study was to investigate the changes in muscle protein synthesis biomarkers and pro-inflammatory factors associated with muscle atrophy in systemic disease. [METHODS] Local muscle tissue damage was observed and compared in both streptozotocin (STZ) -induced diabetic and denervated rats. In these animal models, we measured the expression of muscle-specific IGF-1 (mIGF-1) in by real-time PCR and serum concentrations of inflammatory cytokines by ELISA. In addition, muscle mass and blood glucose levels were observed for six weeks. [RESULTS] The results showed that muscle mass was significantly lower in both experimental groups compared to the control group from week two. Over the six week period, muscle mass gradually increased in the control group, dramatically decreased in the denervated group, but interestingly, showed no significant changes in the diabetes group. Inflammatory factors including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) were significantly higher in diabetic rats than in the control group. The level of TNF-α was increased at week four; however, IL-6 levels did not change in denervated rats. The expression of mIGF-1 mRNA did not change significantly in the two experimental groups. [CONCLUSIONS] In conclusion, mIGF-1 for the proliferation of muscle cells did not have an effect on muscle atrophy among the groups. However the increase in systemic inflammatory factors may be involved in the process of muscle atrophy in diabetic rats.
참고문헌 (42)
- Adams G. R., "Invited Review: Autocrine", paracrine IGF-I and skeletal muscle adaptation, 2002, pp.93, 1159~1167
- Adams G. R., "Time course of changes in markers of myogenesis in overloaded rat skeletal muscles", Jourmal of Applied Physiology, 87, pp.1705~1712 (1999)
- American Diabetes Association, "Diagnosis and Classification of Diabetes Mellitus", Diabetes care, 29, pp.s43~s48 (2006)
- Barbieri M., "Chronic inflammation and the effect of IGF-I on muscle strength and power in older persons", American Journal of Physiologyl Endocrinology and Metabolism, 284, pp.E481~E487 (2003)
- Bongers K. S., "Skeletal muscle denervation causes skeletal muscle atrophy through a pathway that involves both Gadd45a and HDAC4", American Journal of Physiologyl Endocrinology and Metabolism, 305, pp.E907~E915 (2013)
- Brownlee M., "Biochemistry and molecular cell biology of diabetic complications", Nature, 414, pp.813~820 (2001)
- DeVol D. L., "Activation of insulin-like growth factor gene expression during work-induced skeletal muscle growth", American Journal of Physiologyl Endocrinology and Metabolism, 259, pp.E89~E95 (1990)
- Egerman M. A., "Signaling pathways controlling skeletal muscle mass", Critical Reviews in Biochemistry and Molecular Biology, 0, pp.1~10 (2013)
- Eliakim A., "Fitness, Training, and the Growth Hormone→Insulin-Like Growth Factor I Axis in Prepubertal Girls", The Journal of Clinical Endocrinology & Metabolism, 86, pp.2797~2802 (2001)
- Evans, W. J., "Skeletal muscle loss: cachexia, sarcopenia, and inactivity", The American Journal of Clinical Nutrition, 91, pp.1123S~1127S (2010)
- Fan J., "Regulation of insulin-like growth factor (IGF)-I mRNA and peptide and IGF-binding proteins by interleukin-1", American journal of physiology. Regulatory, integrative and comparative physiology, 270, pp.R621~R629 (1996)
- Glass D. J., "Skeletal muscle hypertrophy and atrophy signaling pathways", The International Journal of Biochemistry & Cell Biology, 37, pp.1974~1984 (2005)
- Gosteli-Peter M. A., "Expression and regulation of insulin-like growth factor-I (IGF-I) and IGF-binding protein messenger ribonucleic acid levels in tissues of hypophysectomized rats infused with IGF-I and growth hormone", Endocrinology, 135, pp.2558~2567 (1994)
- Haddad F., "IL-6-induced skeletal muscle atrophy", Jourmal of Applied Physiology, 98, pp.911~917 (2005)
- Hepple R. T., "Muscle atrophy is not always sarcopenia", Jourmal of Applied Physiology, 113, pp.677~679 (2012)
- Holly J. M. P., "The role of growth hormone in diabetes mellitus", Journal of Endocrinology, 118, pp.353~364 (1988)
- Hu G., "Association of Serum C-Reactive Protein Level with Sex-Specific Type 2 Diabetes Risk: A Prospective Finnish Study", The Journal of Clinical Endocrinology & Metabolism, 94, pp.2099~2105 (2009)
- Jaweed M. M., "Denervation and reinnervation of fast and slow muscles. A histochemical study in rats", Journal of Histochemistry & Cytochemistry, 23, pp.808~827 (1975)
- Jørgensen J. O. L., "GH receptor signaling in skeletal muscle and adipose tissue in human subjects following exposure to an intravenous GH bolus", American Journal of Physiologyl Endocrinology and Metabolism, 291, pp.E899~E905 (2006)
- Krause M. P., "Impaired Macrophage and Satellite Cell Infiltration Occurs in a Muscle-Specific Fashion Following Injury in Diabetic Skeletal Muscle", PLoS ONE, 8, pp.e70971~ (2013)
- Masiello P., "Experimental NIDDM: Development of a New Model in Adult Rats Administered Streptozotocin and Nicotinamide", Diabetes, 47, pp.224~229 (1998)
- Midrio M., "The denervated muscle: facts and hypotheses. A historical review", European Journal of Applied Physiology, 98, pp.1~21 (2006)
- Midrio M., "Cordotomy-denervation interactions on contractile and myofibrillar properties of fast and slow muscles in the rat", Experimental Neurology, 100, pp.216~236 (1988)
- Muller F. L., "Denervation-induced skeletal muscle atrophy is associated with increased mitochondrial ROS production", American journal of physiology. Regulatory, integrative and comparative physiology, 293, pp.R1159~R1168 (2007)
- Musaro A., "Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle", Nature Genetics, 27, pp.195~200 (2001)
- Narici M. V., "Sarcopenia: characteristics, mechanisms and functional significance", British Medical Bulletin, 95, pp.139~159 (2010)
- Pedersen B. K., "Muscle as an Endocrine Organ: Focus on Muscle-Derived Interleukin-6", Physiological Reviews, 88, pp.1379~1406 (2008)
- Pellegrino C., "An electron microscope study of denervation atrophy in red and white skeletal muscle fibers", The Journal of Cell Biology, 17, pp.327~349 (1963)
- Philippou A., "The Role of the Insulin-like Growth Factor 1 (IGF-1) in Skeletal Muscle Physiology", In Vivo, 21, pp.45~54 (2007)
- Punkt K., "Effects on skeletal muscle fibres of diabetes and Ginkgo biloba extract treatment", Acta Histochemica, 101, pp.53~69 (1999)
- Reid M. B., "Beyond atrophy: redox mechanisms of muscle dysfunction in chronic inflammatory disease", The Journal of Physiology, 589, pp.2171~2179 (2011)
- Robertson R. P., "Diabetes: Strategies to prevent the type 2 diabetes mellitus epidemic", Nature Reviews Endocrinology, 6, pp.128~129 (2010)
- Rommel C., "Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K", Akt, Akt, pp.GSK3 pathways, Nature Cell Biology[DOI]
- Sacheck J. M., "IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1", American Journal of Physiologyl Endocrinology and Metabolism, 287, pp.E591~E601 (2004)
- Sandri M., "Signaling in Muscle Atrophy and Hypertrophy", Physiology, 23, pp.160~170 (2008)
- Scheett T. P., "Effect of Exercise on Cytokines and Growth Mediators in Prepubertal Children", Pediatric Research, 46, pp.429~429 (1999)
- Shavlakadze T., "Insulin-like growth factor I slows the rate of denervation induced skeletal muscle atrophy", Neuromuscul Disord, 15, pp.139~146 (2005)
- Singleton J. R., "Microvascular Complications of Impaired Glucose Tolerance", Diabetes, 52, pp.2867~2873 (2003)
- Velloso C. P., "Regulation of muscle mass by growth hormone and IGF-I", British Journal of Pharmacology, 154, pp.557~568 (2008)
- Whitman S. A., "Nrf2 modulates contractile and metabolic properties of skeletal muscle in streptozotocin-induced diabetic atrophy", Experimental Cell Research, 319, pp.2673~2683 (2013)
- Wohaieb S. A., "Alterations in free radical tissue-defense mechanisma in streptozotocin-induced diabetic rats", Diabetes, 36, pp.1014~1018 (1987)
- Yach D., "Epidemiologic and economic consequences of the global epidemics of obesity and diabetes", Nature Medicin, 12, pp.62~66 (2006)